Utilizing preclinical models to develop targeted therapies for rare central nervous system cancers.

ABSTRACT: Patients with rare central nervous system (CNS) tumors typically have a poor prognosis and limited therapeutic options. Historically, these cancers have been difficult to study due to small number of patients. Recent technological advances have identified molecular drivers of some of these rare cancers which we can now use to generate representative preclinical models of these diseases. In this review, we outline the advantages and disadvantages of different models, emphasizing the utility of various in vitro and ex vivo models for target discovery and mechanistic inquiry and multiple in vivo models for therapeutic validation. We also highlight recent literature on preclinical model generation and screening approaches for ependymomas, histone mutated high-grade gliomas, and atypical terato

SUBMITTER: Arakaki AKS 

PROVIDER: S-EPMC8561121 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature